Sidney Kimmel Cancer Center

EP. 1: Sidney Kimmel Cancer Center at Thomas Jefferson University Stands Out

May 20th 2016

EP. 2: Dr. Gomella on Using Novel Biomarkers to Inform Biopsy Vs Observation in Prostate Cancer

May 14th 2021

Leonard G. Gomella, MD, discusses using novel biomarkers to inform whether a biopsy is needed in prostate cancer.

EP. 3: Dr. Lipson on the Role of ctDNA Testing in Melanoma

December 8th 2021

Evan J. Lipson, MD, discusses the role of circulating tumor DNA ​testing in melanoma.

EP. 4: Lipson Sheds Light on the Evolving Role of ctDNA in the Realm of Melanoma

December 23rd 2021

Evan J. Lipson, MD, discusses the role of ctDNA in the neoadjuvant, adjuvant, and metastatic settings in the realm of melanoma, remaining questions with this marker, and future directions to optimize its use in this disease.

EP. 5: Brahmer Discusses Influence of 5-Year Nivolumab and Ipilimumab OS Data in Metastatic NSCLC

July 22nd 2022

Julie R. Brahmer, MD, MSc, discusses how data from the CheckMate 227 trial may affect the treatment landscape for NSCLC and notes the quality-of-life outcomes reported with nivolumab and ipilimumab.

EP. 6: Dr. Seedor on Treatment Sequencing in Metastatic Melanoma

August 4th 2022

Rino S. Seedor, MD, discusses findings from the phase 3 DREAMseq trial, which solidified up-front immunotherapy followed by targeted therapy upon progression as a standard of care in patients with BRAF V600–mutant metastatic melanoma.

EP. 7: Dr Zarrabi on Questions Regarding the Use of Triplet Therapy in Prostate Cancer

September 27th 2023

Kevin Kayvan Zarrabi, MD, MS, FACP, discusses remaining questions regarding treatment consisting of triplet therapy in patients with metastatic castration-sensitive prostate cancer.